1MK Stock Overview
A medical device company, manufactures and sells medical devices in Europe and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Mauna Kea Technologies SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.16 |
| 52 Week High | €0.49 |
| 52 Week Low | €0.15 |
| Beta | 1.4 |
| 11 Month Change | -41.37% |
| 3 Month Change | -51.42% |
| 1 Year Change | -61.78% |
| 33 Year Change | -80.15% |
| 5 Year Change | -82.84% |
| Change since IPO | -95.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1MK | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 3.0% | -2.5% | -1.3% |
| 1Y | -61.8% | -8.4% | 7.4% |
Return vs Industry: 1MK underperformed the German Medical Equipment industry which returned -7.1% over the past year.
Return vs Market: 1MK underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| 1MK volatility | |
|---|---|
| 1MK Average Weekly Movement | 16.0% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1MK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1MK's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 65 | Sacha Loiseau | www.maunakeatech.com |
Mauna Kea Technologies SA, a medical device company, manufactures and sells medical devices in Europe and internationally. It offers range of medical devices in gastroenterology, pulmonology, and urology areas. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform which enables physicians to monitor progression of disease over time, assess point-in-time reactions, classify indeterminate areas, and guide surgical interventions.
Mauna Kea Technologies SA Fundamentals Summary
| 1MK fundamental statistics | |
|---|---|
| Market cap | €11.31m |
| Earnings (TTM) | -€11.21m |
| Revenue (TTM) | €8.16m |
1.4x
P/S Ratio-1.0x
P/E RatioIs 1MK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1MK income statement (TTM) | |
|---|---|
| Revenue | €8.16m |
| Cost of Revenue | €2.25m |
| Gross Profit | €5.91m |
| Other Expenses | €17.12m |
| Earnings | -€11.21m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 72.42% |
| Net Profit Margin | -137.49% |
| Debt/Equity Ratio | -137.6% |
How did 1MK perform over the long term?
See historical performance and comparison